Ardelyx, Inc. (NASDAQ:ARDX) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Ardelyx Fourth Quarter and Fiscal Year 2024 Earnings Call.
Ardelyx Inc. (ARDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,963,480 | $15,024,844 | -27% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 2,490,618 | $12,627,433 | +13% | 0% |
| 3. | Two Seas Capital Sina Toussi | 1,855,337 | $9,406,559 | 0.81% | |
| 4. | Rubric Capital Management David Rosen | 1,706,485 | $8,651,879 | -45% | 0.11% |
| 5. | Redmile Group Jeremy Green | 1,576,259 | $7,991,633 | -6% | 0.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 77,729 | Director | 2,015,494 | 2025-02-24 | Filing | |
| $4.99 | 199,000 | Director | 1,937,765 | 2025-01-21 | Filing | |
| $4.67 | 213,300 | Director | 1,638,765 | 2024-12-19 | Filing | |
| $4.62 | 215,868 | Director | 1,425,465 | 2024-11-13 | Filing | |
| $1.76 | 567,000 | Director | 1,166,765 | 2022-11-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.62 | 4,941 | Officer | 303,804 | 2025-02-20 | Filing | |
| $5.62 | 5,171 | Officer | 285,968 | 2025-02-20 | Filing | |
| $5.62 | 22,964 | Officer, Director | 1,085,755 | 2025-02-20 | Filing | |
| $5.62 | 4,291 | Officer | 181,043 | 2025-02-20 | Filing | |
| $5.36 | 41,666 | Officer, Director | 1,108,719 | 2025-01-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,387,941 | $123,587,313 | 0.06% | |
| 2. | 18,521,477 | $93,903,888 | 0% | |
| 3. | 14,362,659 | $72,818,682 | 0% | |
| 4. | 11,592,914 | $58,776,074 | 0% | |
| 5. | 10,346,592 | $52,457,000 | 0.06% |
News See All
12 Best Biotech Penny Stocks To Invest In Now
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call.
Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ardelyx Second Quarter 2024 Conference Call. All participants will be in listen-only mode. [Operator Instructions].
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript
Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Operator: Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
15 Most Shorted Stocks That Are Loved By Analysts
In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts.
5 Best Long-Term Penny Stocks to Buy Now
As of the end of the first quarter of 2023, 20 hedge funds out of the 943 funds in Insider Monkey's database reported owning stakes in Ardelyx, Inc. (NASDAQ:ARDX).
Billionaire Hedge Funds
